Balaxi records Q4 FY21 revenue of Rs. 53 Cr
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
Subscribe To Our Newsletter & Stay Updated